Abstract: The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).
Abstract: Disclosed are compositions, systems and methods for treating keratinous fibers such as hair. The compositions and systems comprise an oxazoline functionalized polymer and a carboxyl group-containing polymer. The compositions and methods are employed to improve the quality of the keratinous fibers.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
November 9, 2021
Assignee:
L'OREAL
Inventors:
Nghi Van Nguyen, Jim Singer, XianZhi Zhou, Jennifer Haghpanah, Charles Shaw
Abstract: The subject disclosure is directed to techniques for enhancing the selectivity and efficacy of therapeutic polymers against a broad spectrum of pathogens and cancer cell lines. According to an embodiment, a method is provided that comprises forming a therapeutic polymer based on polymerization of a plurality of therapeutic monomers, wherein the therapeutic polymer provides a therapeutic functionality. The method further comprises attaching biotin to the therapeutic polymer, resulting in a biotin-functionalized therapeutic polymer, wherein the biotin-functionalized therapeutic polymer provides greater therapeutic efficacy relative to the therapeutic polymer.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
November 9, 2021
Assignees:
INTERNATIONAL BUSINESS MACHINES CORPORATION, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventors:
James L. Hedrick, Nathaniel H. Park, Yi Yan Yang, Zhi Xiang Voo
Abstract: Disclosed are compositions, systems and methods for treating keratinous fibers such as hair. The compositions and systems comprise an oxazoline functionalized polymer and an amino silicone compound. The compositions and methods are employed to improve the quality of the keratinous fibers.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
October 26, 2021
Assignee:
L'OREAL
Inventors:
Nghi Van Nguyen, Jim Singer, XianZhi Zhou, Jennifer Haghpanah, Charles Shaw
Abstract: Disclosed are compositions, systems and methods for treating keratinous fibers such as hair. The compositions and systems comprise an oxazoline functionalized polymer and a compound having at least one nucleophilic site capable of reacting with the at least one oxazoline functionalized compound and chosen from hydroxyl group-containing compounds, thiol group-containing compounds, and a mixture thereof. The compositions and methods are employed to improve the quality of the keratinous fibers.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
October 5, 2021
Assignee:
L'OREAL
Inventors:
Nghi Van Nguyen, Jim Singer, XianZhi Zhou, Jennifer Haghpanah, Charles Shaw
Abstract: Disclosed are compositions, systems and methods for treating keratinous fibers such as hair. The compositions and systems comprise an oxazoline functionalized polymer and a polyamine compound. The compositions and methods are employed to improve the quality of the keratinous fibers.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
September 28, 2021
Assignee:
L'OREAL
Inventors:
Nghi Van Nguyen, Jim Singer, XianZhi Zhou, Jennifer Haghpanah, Charles Shaw
Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.
Type:
Grant
Filed:
June 18, 2019
Date of Patent:
August 31, 2021
Assignee:
Vyne Therapeutics Inc.
Inventors:
Dov Tamarkin, Rita Keynan, David Schuz, Tal Berman
Abstract: Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used.
Type:
Grant
Filed:
December 8, 2009
Date of Patent:
August 17, 2021
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Jason Alan Burdick, Sujata Sahoo, Cindy Chung
Abstract: The present invention provides a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9% by mass of whole structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers containing a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a weakly basic monomer; and a medical patch containing an adhesive composition containing a salt of a basic drug and the star-shaped acrylic block polymer as an adhesive that exhibits high drug efficacy, that does not cause a decrease in adhesive property of an adhesive base due to an additive, and that causes less skin irritation.
Abstract: A biodegradable in vivo supporting device is disclosed. In one embodiment, a coated stent device includes a biodegradable metal alloy scaffold made from a magnesium alloy, iron alloy, zinc alloy, or combination thereof, and the metal scaffold comprises a plurality of metal struts. The metal struts are at least partially covered with a biodegradable polymer coating. A method for making and a method for using a biodegradable in vivo supporting device are also disclosed.
Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.
Abstract: A non-ionic polymer coacervate is provided that is useful for forming adhesive bonds between wet surfaces, and that operates over a wide range of pH.
Abstract: The present invention provides an ?-gel forming composition and an ?-gel composition that uses an ?-gel formation composition that is highly stable and that does not become colored or deposit crystals, etc. over time. An ?-gel composition includes (A) 25-50 mass % of one or more higher aliphatic alcohol and/or higher fatty acid has 16 or more carbons, (B) 40-70 mass % of a specific polyoxyethylene sterol ether, and (C) 5-20 mass % of a specific polyoxyethylene dialkyl ester and/or ether. The ?-gel composition is generated by adding water.
Abstract: A device includes a substrate and a hydrophilic polymer layer made of a hydrophilic polymer having a hydroxyl group. The hydrophilic polymer layer having a hydroxyl group is fixed to at least a part of a surface of the substrate and the hydrophilic polymer further has an amide group. A liquid film retention time of the device is 15 seconds or more. The device has a surface of a substrate which is hydrophilized. A method for producing the device by a simple method is also disclosed.
Abstract: Embodiments of the present disclosure provide for electroactive supramolecular polymeric assemblies, methods of making electroactive supramolecular polymeric assemblies, methods of using electroactive supramolecular polymeric assemblies, and the like.
Type:
Grant
Filed:
April 9, 2020
Date of Patent:
May 18, 2021
Assignee:
University of Florida Research Foundation, Inc.
Abstract: Provided is a dosage form for delivery of a therapeutic agent comprising a polymer matrix comprising arabinogalactan and a therapeutic agent uniformly dispersed in said polymer matrix. In some embodiments, the dosage form is selected from the group consisting of a microsphere, a nanosphere, a powder, a tablet, a film or a pellet enclosed in a capsule. Also provided are methods for preparing the dosage form.
Type:
Grant
Filed:
April 24, 2014
Date of Patent:
May 4, 2021
Assignee:
TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: Compositions and methods regarding guanidinium functionalized polycarbonates that provide potent antimicrobial activity against multidrug resistant (MDR) bacteria, including Klebsiella pneumoniae (K. pneumoniae) are provided. According to an embodiment, an antimicrobial guanidinium-functionalized polymer is provided that comprises a hydrophobic molecular backbone with cationic guanidinium moieties respectively bound to the hydrophobic molecular backbone via butyl spacer groups. The antimicrobial guanidinium-functionalized polymer self-assembles into a micelle structure with hydrophobic residuals of the antimicrobial guanidinium-functionalized polymer buried inside the micelle structure and the cationic guanidinium moieties exposed on an external surface of the micelle structure to target pathogens.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
May 4, 2021
Assignees:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, CORAL BAY II, LLC.
Inventors:
James L. Hedrick, Yi Yan Yang, Chuan Yang
Abstract: This invention relates to medicine, more specifically, to cardiac surgery, and may be used for protecting the heart from ischemia when administering cardioplegia in normothermia or hypothermia. The general-purpose cardioplegic solution contains pharmaceutically acceptable potassium ions; magnesium ions; a base and an acid providing a pH buffer in a range of 7.1-8.9; a diuretic providing osmolality in a range of 275-460 mOsmol/kg. Said solution is used for cardiac protection in cardiopulmonary bypass, as well as for achieving asystole and maintaining the achieved asystole. The procedure for administering the general-purpose cardioplegic solution involves maintaining the achieved asystole by decreasing the flow rate of starting components of said solution relative to the flow rate of autoblood thus decreasing the solution to autoblood ratio.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
April 27, 2021
Assignee:
LIMITED LIABILITY COMPANY “CARDIOSYSTEMPHARMA” (LLC “CSP”)
Abstract: Provided is a polymeric micelle type DDS preparation that may efficiently exhibit pharmacological activity effects by enhancing migration characteristics, penetrability, and retention characteristics toward a diseased target tissue such as a tumor tissue or an inflammation-affected tissue, and thereby enhancing the action of a pharmacologically active substance. Disclosed is a block copolymer (A) having a hydrophilic polymer segment linked to a hydrophobic polymer segment, the hydrophilic polymer segment containing a polyethylene glycol chain, and the hydrophobic polymer segment containing a polyamino acid chain having a hydrophobic substituent in a side chain, wherein the hydrophilic polymer segment has a target binding site bonded thereto, and the main chain polymer combining the polyethylene glycol chain and the polyamino acid chain has a molecular weight of not less than 2 kilodaltons and not more than 10 kilodaltons.
Type:
Grant
Filed:
July 25, 2017
Date of Patent:
April 13, 2021
Assignee:
Nippon Kayaku Kabushiki Kaisha
Inventors:
Dai Kurihara, Tsuyoshi Fukuda, Yuki Kawano, Keiichirou Yamamoto